Research programme: carnitine O-palmitoyltransferase inhibitors - DARA BioSciences

Drug Profile

Research programme: carnitine O-palmitoyltransferase inhibitors - DARA BioSciences

Alternative Names: DB200; VX100

Latest Information Update: 17 Feb 2012

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valexx Pharmaceuticals
  • Developer Midatech Pharma US
  • Class Small molecules
  • Mechanism of Action Carnitine O-palmitoyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Psoriasis

Most Recent Events

  • 15 Feb 2012 Research programme: carnitine O-palmitoyltransferase inhibitors - DARA BioSciences is available for licensing as of 15 Feb 2012. http://www.darabio.com
  • 02 Jul 2008 Preclinical development is ongoing
  • 27 Jul 2007 Preclinical trials in Psoriasis in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top